-
Mashup Score: 1Webprogram Unavailable - 12 month(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Background: Belantamab mafodotin (belamaf) is a first-in-class antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Belamaf has shown clini
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@DrPaulyDeSantis @DrAlexisTalbot I like ALGONQUIN! From #ASH22 by Dr. Trudel @HiraSMian et al. Why have belantamab and pom-dex be foes when they could be friends 😉 https://t.co/mMyp88d8N5
-
-
Mashup Score: 0Webprogram Unavailable - 1 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
BMT w/in 4 wks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study [Sat, Dec 10, 2022] @MeeraMohanMD Abst 387 #ASH22 https://t.co/4MtPzSAUAs #COVID19nCancer #bmtsm #IDonc #COVID19 #AMLsm #leusm OR 49.6 📷 https://t.co/2Dw8odAO0b
-
-
Mashup Score: 1
Kelsey Natsuhara discusses her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation.
Source: Oncology Data AdvisorCategories: Hem/Oncs, Latest HeadlinesTweet-
3/ Pleasure mentoring @KelseyNatsuhara on this - she did an AMAZING job as a @UCSFCancer fellow and even got interviewed about her first-author #ASH22 abstract! https://t.co/wVxMZzdoso And 🙏 @ninashah33 and @SandyWong02111 for mentorship behind the scenes to make this happen!
-
-
Mashup Score: 0
Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinicians treating pts w/ leukemia have gained more effective treatment options, including new therapeutic approaches for pts w/ ALL, CML, and AML. @sameem_abedin @MedicalCollege @MDAndersonNews @DukeCancer @CleClinicLCM @ASH_hematology #leusm #ASH22 https://t.co/e6PruFX4rH https://t.co/7XYahuR8DJ
-
-
Mashup Score: 0
Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Elias Jabbour, MD, of@MDAndersonNews, Harry Erba, MD, PhD, of @DukeCancer, Anjali Advani, MD, of @CleClinicLCM, & @sameem_abedin, of @MedicalCollege, discuss updates in leukemia treatment from #ASH22. @ASH_hematology #leusm https://t.co/DXJxV9WDdU
-
-
Mashup Score: 3Highlights of ASH in Latin America - 1 year(s) ago
Last Revised: May 1, 2018 Thank you for your interest in how ASH uses cookies on our Sites. We have provided this Cookie Policy to provide you with transparency so you can make informed choices about how your personal data in the form of your internet protocol address is tracked utilizing cookies by ASH and other third parties. This Cookie Policy explains how your personal data is shared and…
Source: www.hematology.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Acompáñenos en São Paulo para Highlights of ASH en América Latina y forme conexiones con profesionales de #hematología en la región 🌍🥼 Regístrese hoy para un resumen de la ciencia más destacada de #ASH22: https://t.co/VE3FjVhtgn https://t.co/0iBvU32gCb
-
-
Mashup Score: 2Highlights of ASH in Latin America - 1 year(s) ago
Last Revised: May 1, 2018 Thank you for your interest in how ASH uses cookies on our Sites. We have provided this Cookie Policy to provide you with transparency so you can make informed choices about how your personal data in the form of your internet protocol address is tracked utilizing cookies by ASH and other third parties. This Cookie Policy explains how your personal data is shared and…
Source: www.hematology.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Junte-se a nós no Highlights da ASH na América Latina em São Paulo e conecte-se com os principais especialistas em #hematologia do mundo 🌍🥼 Recapitule os resumos de maior destaque do #ASH22. Inscreva-se hoje! https://t.co/t5KlrKKSfV
-
-
Mashup Score: 0Venetoclax With FLAG-IDA Yielded High Remission and Transition to Transplant Rates in Patients With R/R Acute Myeloid Leukemia - 1 year(s) ago
An updated phase 2b study found that the combination of venetoclax and FLAG-IDA therapy for patients with R/R AML resulted in deep remission and a high rate of transition to transplant.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A phase 2b study presented at the #ASH22 Annual Meeting and Exposition found that venetoclax and FLAG-IDA therapy for patients with R/R #AML resulted in deep remission and a high rate of transition to transplant. Click to learn more! @MDAndersonNews https://t.co/wtiODho6iJ https://t.co/LVRb5Sj3mQ
-
-
Mashup Score: 0Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL - 1 year(s) ago
Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a featured video, Talha Munir, MD discusses findings from an exploratory analysis of the phase 2 CLARITY trial which he presented at the #ASH22 Annual Meeting & Exposition. Click below to learn more! https://t.co/693UBxm84a https://t.co/qpbbv9ZW1d
-
BMT w/in 4 wks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study [Sat, Dec 10, 2022] @MeeraMohanMD Abst 387 #ASH22 https://t.co/4MtPzSAUAs #COVID19nCancer #bmtsm #IDonc #COVID19 #AMLsm #leusm OR 49.6 https://t.co/lobskdXaiH